BIOSPECIFICS TECHNOLOGIES CORP.

INVESTIGATION ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Merger Investigations; Investors are Encouraged to Contact the Firm - CIT, CXO, BSTC, CBLI, PNM

Retrieved on: 
Thursday, November 12, 2020
Stock market, Financial economics, Finance, Corporate finance, Common law, Equity, Fiduciary, Stock, ConocoPhillips, Shareholder

If you are a CIT Group shareholder, click on this link to learn more about your legal rights and options: https://halpersadeh.com/actions/cit-group-inc-stock-merger-first-citizens/ .

Key Points: 
  • If you are a CIT Group shareholder, click on this link to learn more about your legal rights and options: https://halpersadeh.com/actions/cit-group-inc-stock-merger-first-citizens/ .
  • Concho Resources Inc. (NYSE: CXO)concerning potential violations ofthe federal securities laws and/or breaches of fiduciary duties relating to its sale to ConocoPhillips.
  • Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options.

BioSpecifics to Present at the H.C. Wainwright Virtual Healthcare Conference

Retrieved on: 
Tuesday, September 8, 2020
Communication, Forward-looking statement, REPLAY, Software, Articles, Human activities

A live webcast of the presentations may be accessed by visiting the Events and Presentations section of the BioSpecifics website at https://investors.biospecifics.com .

Key Points: 
  • A live webcast of the presentations may be accessed by visiting the Events and Presentations section of the BioSpecifics website at https://investors.biospecifics.com .
  • An archived replay of the webcast will be available on the Company's website for approximately 90 days following the presentation.
  • These forward-looking statements are predictions based on the Company's current expectations and the Company's projections about future events and various assumptions.
  • There can be no assurance that the Company will realize its expectations or that the Company's beliefs will prove correct.

BioSpecifics Appoints Alex Monteith as Chief Business Officer

Retrieved on: 
Monday, July 20, 2020
Monteith

WILMINGTON, Del., July 20, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) (the "Company"), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX in North America, today announced the appointment of Alex Monteith as Senior Vice President and Chief Business Officer.

Key Points: 
  • WILMINGTON, Del., July 20, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) (the "Company"), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX in North America, today announced the appointment of Alex Monteith as Senior Vice President and Chief Business Officer.
  • Mr. Monteith was most recently Vice President of Business Development for Deerfield Management, LLC, where he helped establish and lead the business development function as part of the Operations Team.
  • Previously, he served as Vice President of Business Development & Alliance Management for Achillion Pharmaceuticals, Inc. ("Achillion"), a clinical-stage biopharmaceutical company.
  • There can be no assurance that the Company will realize its expectations or that the Company's beliefs will prove correct.

BioSpecifics Reports First Quarter 2020 Financial and Operating Results

Retrieved on: 
Monday, May 11, 2020

Total revenue for the first quarter ended March 31, 2020 was $9.7 million, compared to $8.1 million for the same period in 2019.

Key Points: 
  • Total revenue for the first quarter ended March 31, 2020 was $9.7 million, compared to $8.1 million for the same period in 2019.
  • Research and development expenses for the first quarter ended March 31, 2020 were $0.1 million compared to $0.1 million for the same period in 2019.
  • General and administrative expenses for the first quarter ended March 31, 2020 were $3.2 million, compared to $2.9 million for the same period in 2019.
  • Restructuring charges related to the relocation of the Company's headquarters and the separation of certain employees were $1.1 million for the first quarter ended March 31, 2020.

BioSpecifics Names Joseph Truitt as Permanent Chief Executive Officer

Retrieved on: 
Monday, May 11, 2020

Mr. Truitt was appointed interim Chief Executive Officer by the Company's Board of Directors on April 6, 2020 and assumed this permanent role on May 7, 2020.

Key Points: 
  • Mr. Truitt was appointed interim Chief Executive Officer by the Company's Board of Directors on April 6, 2020 and assumed this permanent role on May 7, 2020.
  • Prior to joining BioSpecifics, Mr. Truitt was most recently Chief Executive Officer of Achillion Pharmaceuticals, Inc.
  • He joined the company in 2009 and had previous roles of Chief Operations Officer and Chief Commercial Officer.
  • I look forward to building an even greater future for BioSpecifics and improving many more patients' lives," said Joseph Truitt, Chief Executive Officer of BioSpecifics.

BioSpecifics Appoints Mike Sherman and Corey Fishman to Board of Directors

Retrieved on: 
Thursday, April 9, 2020
Companies, Business, Corporations, Committees, Corporate law, Corporate governance, Auditing, Reckitt Benckiser, Mead Johnson, Audit committee, Audit, Board of directors

Mike Sherman and Corey Fishman will both join the Board's Audit Committee, with Mr. Sherman serving as an "audit committee financial expert."

Key Points: 
  • Mike Sherman and Corey Fishman will both join the Board's Audit Committee, with Mr. Sherman serving as an "audit committee financial expert."
  • We believe our newest members will make significant contributions to the future outlook of the Company," said Jennifer Chao, Chairman of the Board of Directors.
  • He also served on the Board of Directors at Mead Johnson Nutrition until the company's acquisition by Reckitt Benckiser.
  • Mr. Fishman currently serves as Chair of the Audit Committee of the Board of Directors of Momenta Pharmaceutics, Inc.
    BioSpecifics Technologies Corp. (BioSpecifics) is a commercial-stage biopharmaceutical company.

BioSpecifics Appoints Joseph Truitt as Interim Chief Executive Officer

Retrieved on: 
Thursday, April 9, 2020

WILIMINGTON, Del., April 9, 2020 /PRNewswire/ --BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX in North America, today announced that the Board of Directors has appointed Joseph Truitt as interim Chief Executive Officer.

Key Points: 
  • WILIMINGTON, Del., April 9, 2020 /PRNewswire/ --BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX in North America, today announced that the Board of Directors has appointed Joseph Truitt as interim Chief Executive Officer.
  • Prior to joining BioSpecifics, Mr. Truitt was most recently Chief Executive Officer of Achillion Pharmaceuticals, Inc. since May 2018.
  • He joined the company in 2009 and had previous roles of Chief Operations Officer and Chief Commercial Officer.
  • There are very significant value creation opportunities and I look forward to working closely with the Board of Directors and team to fully execute on the Company's clearly defined corporate objectives," said Joseph Truitt, interim Chief Executive Officer.

Jennifer Chao Appointed Chairperson of BioSpecifics Technologies Corp. Board of Directors

Retrieved on: 
Wednesday, October 23, 2019
Video game characters, Fictional characters, Chao, Board of directors, Lynbrook

LYNBROOK, N.Y., Oct. 23, 2019 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class product marketed as XIAFLEXin the U.S. and XiapexinEurope, today announced that Jennifer Chao has been appointed chairperson of its board of directors, effective immediately.

Key Points: 
  • LYNBROOK, N.Y., Oct. 23, 2019 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class product marketed as XIAFLEXin the U.S. and XiapexinEurope, today announced that Jennifer Chao has been appointed chairperson of its board of directors, effective immediately.
  • Ms. Chao has served on the BioSpecifics board as an independent director since 2015, and also serves as chair of the compensation committee.
  • "Jenn's counsel as chairperson of our board will be instrumental as we seek to unlock new opportunities to generate value for all our stakeholders.
  • Except as may be required by law, BioSpecifics assumes no obligation to update these forward-looking statements.

BioSpecifics Technologies Corp. Names J. Kevin Buchi as Chief Executive Officer

Retrieved on: 
Thursday, October 10, 2019
Pharmaceutical companies, Companies, Cephalon, Industries, Teva Pharmaceutical Industries, Amneal Pharmaceuticals, Impax

LYNBROOK, N.Y., Oct. 10, 2019 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEXin the U.S. and Xiapexin Europe, today named life sciences industry veteran Kevin Buchi chief executive officer of BioSpecifics.

Key Points: 
  • LYNBROOK, N.Y., Oct. 10, 2019 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEXin the U.S. and Xiapexin Europe, today named life sciences industry veteran Kevin Buchi chief executive officer of BioSpecifics.
  • "We are extremely pleased to have Kevin join BioSpecifics as chief executive officer.
  • Previously, he served as Impax Laboratories' interim President and chief executive officer from December 2016 to March 2017.
  • Mr. Buchi also served as chief executive officer of Cephalon, which was acquired by Teva in October 2011.

BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2018 Financial Results

Retrieved on: 
Tuesday, April 2, 2019

Total revenue for the fourth quarter ended December 31, 2018 was $9.9 million, compared to $6.7 million for the same period in 2017.

Key Points: 
  • Total revenue for the fourth quarter ended December 31, 2018 was $9.9 million, compared to $6.7 million for the same period in 2017.
  • No licensing revenue was recognized for the fourth quarter ended December 31, 2018 as compared to approximately $4,000 for the same period in 2017.
  • General and administrative expenses for the fourth quarter ended December 31, 2018 were $2.5 million, compared to $1.6 million for the same period in 2017.
  • Provision for income taxes for the fourth quarter ended December 31, 2018 were $1.5 million, compared to $2.4 million for the same period in 2017.